

# miR-210-3p Promotes Lung Cancer Development and Progression by Modulating USF1 and PCGF3

Qian Chen <sup>1,2,\*</sup>  
 Hongyu Zhang <sup>3,4,\*</sup>  
 Jianyin Zhang <sup>1,2</sup>  
 Le Shen <sup>1,2</sup>  
 Jing Yang <sup>1,2</sup>  
 Yan Wang <sup>1,2</sup>  
 JinXiu Ma <sup>1,2</sup>  
 Bing Zhuan <sup>1,2</sup>

<sup>1</sup>Department of Respiratory Medicine, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, People's Republic of China; <sup>2</sup>Department of Respiratory Medicine, First Affiliated Hospital of Northwest Minzu University, Yinchuan, People's Republic of China; <sup>3</sup>Department of Intervention and Vascular Surgery, People's Hospital of Ningxia Hui Autonomous, Yinchuan, People's Republic of China; <sup>4</sup>Department of Intervention and Vascular Surgery, First Affiliated Hospital of Northwest Minzu University, Yinchuan, People's Republic of China

\*These authors contributed equally to this work

**Purpose:** Lung cancer represents one of the most frequent solid tumors. Adenocarcinoma is a common type of tumor and a significant threat to individual health globally. MicroRNAs (miRNAs) are recognized as critical governors of gene expression during carcinogenesis, while their effects on lung cancer occurrence and development are required for further investigation. Herein, the functional role of miR-210-3p and its regulation mechanism were characterized in lung cancer.

**Methods:** A total of 50 pairs of tumor and tumor-free lung tissues were surgically resected from lung cancer patients. Dual-luciferase reporter assay and RNA immunoprecipitation assay were performed to examine USF1 binding with miR-210-3p and PCGF3. Cultured human lung cancer cells A549 were assayed for viability, apoptosis, migration, and invasion in vitro by CCK-8 test, flow cytometry, transwell chamber assays, tumorigenesis, and lymph node metastasis in vivo by mouse xenograft experiments.

**Results:** miR-210-3p was upregulated in lung cancer tissues. The inhibition of miR-210-3p by specific inhibitor tempered lung cancer development and metastasis in vitro and in vivo. miR-210-3p targeted USF1 and inhibited its expression. USF1 was bound with PCGF3, which increased its transcription. PCGF3-specific knockdown mimicked the effect of miR-210-3p on lung cancer development and metastasis in vitro and in vivo.

**Conclusion:** The current study demonstrated that miR-210-3p facilitates lung cancer development and metastasis by impairing USF1-mediated promotion of PCGF3, which provides a better understanding of the mechanism of lung cancer development and metastasis.

**Keywords:** lung cancer, miR-210-3p, USF1, PCGF3

## Introduction

Lung cancer, together with liver and colorectal cancer, remains a leading cause of cancer-related deaths worldwide, and 80% of lung cancers belong to non-small cell lung cancers (NSCLCs).<sup>1</sup> Reportedly, numerous risk factors, including tobacco use, occupational carcinogens, exposure to radon, and environmental deterioration, are responsible for lung cancer.<sup>2</sup> The incidence rate of lung cancer is rising, and the prognosis is poor.<sup>3</sup> In the recent three decades, the 5-year survival of patients with lung cancer remains only 19%, with minimal improvement.<sup>4</sup> Thus, it is imperative to explore the underlying molecular mechanisms and identify the novel prognostic biomarkers and potential therapeutic targets for lung cancer.

MicroRNAs (miRNAs) are endogenous small non-coding single-stranded RNAs that regulate the expression of downstream genes by binding with the 3'-untranslated region (3'-UTR) of the target mRNAs.<sup>5</sup> Accumulating evidence revealed that several miRNAs are involved in the regulation of diverse

Correspondence: Bing Zhuan  
 Department of Respiratory Medicine,  
 First Affiliated Hospital of Northwest  
 Minzu University, No. 301 Zhengyuan  
 North Street, Jinfeng District, Yinchuan,  
 750004, People's Republic of China  
 Tel +86 18709518179  
 Email Zhuanb518@163.com

biological processes, such as cancer cell proliferation, apoptosis, and metastasis.<sup>6</sup> The dysregulation of miRNAs has been validated in the initiation and development of lung cancer.<sup>7</sup> For example, miRNA-148a is significantly downregulated in primary NSCLC tissues and can inhibit NSCLC cell migration and invasion by targeting Wnt1.<sup>8</sup> miRNA-744-5p shows a decreased expression in NSCLC cell lines, while overexpression of miRNA-744-5p inhibits NSCLC cell proliferation, colony formation, and cell invasion in vitro by targeting paired box 2.<sup>9</sup> Moreover, miR-210-3p is known to be involved in multiple human cancers, such as bladder cancer, breast cancer, and gastric carcinoma, via regulation of a series of target genes.<sup>10</sup> Zhang et al demonstrated that miR-210-3p is a promising biomarker for the treatment of lung cancer.<sup>11</sup> In addition, microarray analysis in the present study has proven that upstream stimulating factor 1 (*USF1*) is a target gene of miR-210-3p. *USF1* is regarded as a common transcription factor in mammalian cells, which is isolated from HeLa cells and encodes a 43-kDa polypeptide.<sup>12</sup> Also, the effects of *USF1* have been demonstrated in lung cancer.<sup>13</sup> Furthermore, *USF1* DNA binding transcription factor interacts with PCGF3 protein, encoded by the gene.<sup>14</sup> The protein consists of a C3HC4-type RING finger, which is a known motif implicated in protein–protein interaction, and the expression of RING1 protein might be an independent prognostic indicator for NSCLC,<sup>15</sup> but it is unclear whether PCGF3 may be involved in tumor progression in patients with lung cancer. Nevertheless, understanding of the pivotal miR-210-3p/*USF1*/PCGF3 axis associated significantly with the progression of lung cancer is limited. Therefore, the present study aimed to explore the role of the discovered miR-210-3p/*USF1*/PCGF3 axis in the pathogenesis of lung adenocarcinoma and the underlying mechanisms, which might provide a novel direction for treating lung adenocarcinoma.

## Materials and Methods

### Ethics Statement

Informed consent was obtained from the subjects, and the protocol was approved by the Ethics Committee of People's Hospital of Ningxia Hui Autonomous Region. The animal studies were approved by the Institutional Animal Care and Use Committee of the hospital. The experimental procedures complied with the Helsinki

declaration. All animal experiments were carried out according to the published recommendations in the Guide for the Care and Use of Laboratory Animals with minimum suffering.

### Human Tissue Specimen Collection

A total of 50 pairs of tumor and adjacent tumor lung tissues were surgically resected from lung cancer patients (28 males and 22 females) admitted to our hospital from January 2010 to January 2014. None of the patients had received radiotherapy, chemotherapy, or immunotherapy before surgery. The age of 50 NSCLC patients was 23–80 (average,  $51.22 \pm 9.50$ ) years. After surgery, all patients were followed up for 8–60 months until January 2019. The overall survival was defined as the time duration from exenteration to the last contact or date of death, and the overall survival probabilities were estimated using the Kaplan–Meier method.

### Cell Lines

We purchased four types of human lung cancer cell lines, A549 (3111C0001CCC000002), A-427 (3111C0001CCC000213), NCI-H209 (3111C0001CCC000045), and NCI-H23 (3111C0001CCC000255), two types of human normal lung epithelial cell line BEAS-2B (3131C0001000200027), and embryonic lung fibroblast cell MRC-5 (3111C0001CCC000044) from the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences. A549, A-427, NCI-H23, and MRC-5 cells were cultured in the medium containing 8% DMSO and 20% fetal bovine serum (FBS), NCI-H209 in 20% FBS/RPMI1640 (w/o HEPES), and BEAS-2B cells were cultured in 10% FBS/DMEM (high glucose). The cells were cultured in the incubator (37 °C, 5% CO<sub>2</sub>) (Jinan Beisheng Medical Devices Inc., Shandong, China).

### RNA Interference

Based on the oligonucleotides of *USF1* and *PCGF3* genes in the GenBank of the National Center for Biotechnology Information (NCBI) database, *USF1*- and *PCGF3*-specific shRNA were designed. Subsequently, we identified two shRNAs for *USF1* (named sh-*USF1*-1 and sh-*USF1*-2) and two for *PCGF3* (named sh-*PCGF3*-1 and sh-*PCGF3*-2) using BLAST. These shRNAs were constructed into pGPU6/Neo vectors (C02003, GenePharma, China) and transformed into MRC-5 cells, with scrambled shRNA as the negative control, respectively. The sequences are listed in Table 1.

## Luciferase Assays

Oligonucleotides on the 3'UTR of *USF1* mRNA containing the putative miR-210-3p binding sites (USF1-Wt) and oligonucleotides on the 3'UTR of *PCGF3* mRNA containing the putative USF1 binding sites (PCGF3-Wt) were inserted into the pMIR-reporter vectors (Beijing Huayueyang Biotechnology Co., Ltd, Beijing, China) on *SpeI* and *HindIII* sites, respectively. Next, we mutated the putative miR-210-3p binding sites on the 3'UTR of *USF1* mRNA (USF1-Mut) and the putative USF1 binding sites on the 3'UTR of *PCGF3* mRNA (named PCGF3-Mut) and inserted these mutant oligonucleotides into the pMIR-reporter vectors, respectively. The reporter vectors containing USF1-Wt or USF1-Mut with miR-210-3p mimic were transfected into HEK-293T cells; also, the reporter vectors containing PCGF3-Wt or PCGF3-Mut plus USF1 were transfected into HEK-293T cells. The overexpression vector of USF1 (named oe-USF1) connects the CDS region to the vector pcDNA3.1. The luminescence of firefly luciferase was determined using dual-luciferase reporter assay system kit (K801-200, BioVision, Milpitas, CA, USA) and Glomax 20/20 luminometer (Promega, Madison, WI, USA) as per the instructions provided by the manufacturer and normalized to that of renilla luciferase. All vectors and miR-210-3p mimic were purchased from GenePharma. The primers of clonal and mutant PCR are listed in [Supplementary Table 1](#).

## RNA Immunoprecipitation (RIP) Assays

A correlation was evaluated between USF1 and AGO2 using a commercial kit (Millipore, Billerica, MA, USA) in accordance with the manufacturer's instructions. Briefly, A549 cells were lysed, and extracts were obtained by centrifugation (14,000 ×g, 4°C, 10 min). The cell extracts were immunoprecipitated with protein A/G Sepharose beads conjugated with either anti-AGO2 antibody (ab32381, 1:50, Abcam, UK) or normal mouse IgG (ab109489, 1:100, Abcam). After incubation with proteinase K (New England Biolabs, Beverly, MA, USA), immunoprecipitated RNA and total RNA and input controls were extracted for real-time quantitative polymerase chain reaction (qPCR) analysis using *USF1*-specific primer sequences.

## Chromatin Immunoprecipitation (ChIP) Assays

The enrichment of *USF1* in the *PCGF3* promoter region was evaluated by ChIP assay following the instructions

provided by the kit's manufacturer (Millipore). Briefly, A549 cells were fixed with 10% formaldehyde for 10 min to generate DNA-protein cross-links. The cell lysates were sonicated to generate chromatin fragments, following which, chromatin fragments were split into three parts: two were immunoprecipitated with either anti-USF1 antibody (ab125020, 1:10,000, Abcam) or normal mouse IgG (ab172730, 1:1000, Abcam) at 4 °C overnight. The third part is used for quality inspection of DNA lysis. The DNA-protein complexes were precipitated using Protein Agarose/Sepharose (BioVision, Milpitas, CA, USA). The immunoprecipitate was de-crosslinked, and the DNA samples were extracted by a standard phenol/chloroform procedure and analyzed by real-time qPCR analysis using *PCGF3*-specific primer sequences (forward: 5'-AAGGCTATTTCCTACTCCC-3', reverse: 5'-CGCTCGCTTCTGAATACCTC-3').

## Real-Time qPCR

Total RNA was extracted from A549 cells in mouse tumor xenografts were obtained using TRIzol reagents (15596026, Invitrogen, Carlsbad, CA, USA) and reverse transcribed into cDNA using a commercially available kit (RR047A, TaKaRa, Tokyo, Japan) in accordance with the manufacturer's protocol. Real-time qPCR was performed using TaqMan MicroRNA Assay and TaqMan® Universal PCR Master Mix to quantify the expression of miR-210-3p, against *U6* mRNA expression for normalization. Then, real-time qPCR was performed using the SYBR Premix EX Taq kit (RR420A, TaKaRa) to quantify the expression of *ASCL1*, *SIN3A*, *USF1*, *STAT1*, and *YY1*, against  $\beta$ -actin mRNA expression for normalization. Real-time qPCR was carried out on the ABI PRISM®7300 instrument (Applied Biosystems, USA). Data were calculated by using  $2^{-\Delta\Delta CT}$  method. Primers ([Table 2](#)) were synthesized by Sangon (Shanghai, China).

**Table 1** Oligonucleotides of Two Pieces of USF1-Specific shRNA, Two Pieces of PCGF3-Specific shRNA and Scrambled shRNA

shRNA	Oligonucleotides (5'-3')
sh-USF1-1	5'-CCCTTGATCTCAGCTGGATTCTCTT-3'
sh-USF2-2	5'-CGGCTTCTTTCCGGCTTCACAAATA-3'
sh-PCGF3-1	5'-ACCGAGTGCTTACACACCTTCTGTA-3'
sh-PCGF3-2	5'-CACCTTCTGTAGAAGCTGCCTTGTA-3'
Scrambled shRNA	5'-TTCTCCGAACGTGTCACGTTT-3'

## Immunoblotting

Proteins were extracted from A549 cells in mouse tumor xenografts. An equivalent of 30 µg protein samples was separated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (AP15L534, LIFE iLAB BIO Technology CO., LTD. Shanghai, China) (80 V/35 min, 120 V/45 min) and transferred to the polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA, USA). The membranes were probed with rabbit anti-USF1 antibody (ab125020, 1:10,000, Abcam), anti-PCGF3 antibody (ab210804, 1:500, Abcam), anti-MMP-2 antibody (ab125020, 1:1000, Abcam), anti-MMP-9 antibody (ab73734, 1:1000, Abcam), anti-Bcl-2 antibody (ab182858, 1:2000, Abcam), anti-Bax antibody (ab32503, 1:2000, Abcam), and anti-GAPDH antibody (ab181602, 1:10,000, Abcam), and then incubated with the corresponding horseradish peroxidase-labeled IgG antibody (ab6721, 1:10,000, Abcam). GAPDH was used as a loading control for normalization. The immunoreactive bands were visualized using the enhanced chemiluminescence (ECL) method (BB-3501, Amersham, UK) according to the manufacturer's protocol. Image Pro Plus software (version 6.0, Media Cybernetics Inc., Rockville, MD, USA) was used to analyze the gray value of each band against GAPDH as the internal reference for relative quantitative analysis of the target protein.

## CCK-8 Assays

A549 cells were cultured for 0, 1, 2, 3, and 4 days. Then, 10 µL CCK-8 reagent was added to each well and incubated for an additional 4 h. The absorbance (at 450 nm) was measured on a Microplate reader (BioTek, Vermont, USA), and growth curves plotted.

## Flow Cytometric Analysis

A549 cells ( $1 \times 10^6$ /mL) were stained with fluorescein isothiocyanate (FITC)-Annexin V/propidium iodide (PI) (Shanghai Shuojia Biotechnology, China) for 15–30 min in the dark. Flow cytometer (XL, Coulter, USA) was used to detect apoptosis at the emission wavelength of 530 nm (FITC-Annexin V) and >575 nm (PI).

## Transwell Migration and Invasion Assays

The transwell chamber system (3413, Beijing Youni Biotechnology, China) was used for cell migration and invasion assays. For cell migration assays, A549 cells

( $1 \times 10^6$  cells/mL) in 100 µL serum-free DMEM were added into the upper chambers. For cell invasion assays, A549 cells were added into the upper chambers coated with 50 µL Matrigel (40111ES08, YeaSen Biotechnology, Shanghai, China) pre-diluted (1:1) with serum-free DMEM. After incubation for 24 h, the cells that migrated to the lower chamber containing 500 µL 20% FBS-supplemented DMEM (for cell migration assays) and 600 µL 20% FBS-supplemented DMEM (for cell invasion assays) were subject to fixation with 5% glutaraldehyde and 0.1% crystal violet staining. The stained cells were counted in five microscopic fields (TE2000, Nikon, China) per well, and the average was calculated.

## Mouse Xenograft Experiments

A total of 18 BALB/c mice (equal number of males and females), aged 4–5 weeks and weighing 18 to 22 g (The Laboratory Animal Center of Ningxia Medical University, China), were maintained specific pathogen-free conditions. A549 cells were adjusted into suspensions ( $5 \times 10^6$  cells/mL) using 10 mg/mL Matrigel (40111ES08, YeaSen Biotechnology, Shanghai, China), and 0.2 mL of suspensions with  $1 \times 10^6$  cells were implanted subcutaneously into the scapular region of each mouse. Intravenous injection of miR-210-3p antagomir (GenePharma) alone or with PCGF3-specific shRNA was administered into mice xenografted with A549 cells after implantation duration of 8 days. Briefly, 12.5 µg oligonucleotides were diluted into 1 µg/µL and mixed with 12.5 µL water and 25 µL of 10% glucose solution (w/v) to supplement a final volume of 50 µL. Simultaneously, Entranster™ in vivo reagents (18668-11-1, Engreen, China) were mixed with 25 µL of 10% glucose solution (w/v) to a final volume of 50 µL. A mixture of oligonucleotides and Entranster in vivo reagents was injected into each mouse by the tail vein, rendering a final concentration of 100 µg and 50 µL Entranster. The growth of lung cancer xenografts in mice was monitored every 3 days after implantation duration of 8 days. At 32 days after implantation, the mice were euthanized by CO<sub>2</sub> suffocation, following which tumor xenografts were excised and lymph nodes surrounding the tumor xenografts resected for hematoxylin-eosin (HE) staining.

## Statistical Analysis

Data (mean ± standard deviation) were representative of three independent experiments (each in triplicate) and

**Table 2** Primer Sequences Used for Real-Time qPCR Analysis

Target	Primer Sequences (5'-3')
miR-210-3p	F: 5'-GTGCAGGGTCCGAGGT-3' R: 5'-CTGTGCGTGTGACAGCGGCTGA-3'
ASCL1	F: 5'-CCCAAGCAAGTCAAGCGACA-3' R: 5'-AAGCCGCTGAAGTTGAGCC-3'
SIN3A	F: 5'-ACCATGCAGTCAGCTACGG-3' R: 5'-CACCGCTGTTGGGTGATGA-3'
USFI	F: 5'-CTGCTGTTGTTACTACCCAGG-3' R: 5'-TCTGACTTCGGGAATAAGGG-3'
STAT1	F: 5'-CAGCTTGACTCAAAATTCCTGGA-3' R: 5'-TGAAGATTACGCTTGCTTTTCCT-3'
YY1	F: 5'-ACGGCTTCGAGGATCAGATTC-3' R: 5'-TGACCAGCGTTTGTCAATGT-3'
$\beta$ -actin	F: 5'-AAGAGCTACGAGCTGCCTGA-3' R: 5'-GGCAGTGATCTCCTTCTGCA-3'
U6	F: 5'-GGCTGGTAAGGATGAAGG-3' R: 5'-TGGAAGGAGGTCATACGG-3'

**Abbreviations:** F, forward; R, reverse.

analyzed using SPSS 21.0 software (IBM, Armonk, NY, USA), with two-tailed  $p < 0.05$  as a level of statistical significance. For statistical comparison, paired or unpaired  $t$ -test, a one-way analysis of variance (ANOVA) with Tukey's test, and repeated measurements ANOVA with Bonferroni test were performed.

## Results

### Upregulated miR-210-3p Was Associated with a Poor Prognosis of Lung Cancer

To identify the expression pattern of miR-210-3p in lung cancer, we quantified the expression of miR-210-3p in 50 tumor lung tissues and matched tumor-free lung tissues by real-time qPCR. The results showed that the expression of miR-210-3p was elevated in tumor lung tissues compared to matched tumor-free lung tissues (Figure 1A). Similarly, we compared the expression of miR-210-3p between lung cancer cell lines (A549, A-427, NCI-H209, and NCI-H23) and normal embryonic lung fibroblast cell line HBE using real-time qPCR. Interestingly, all lung cancer cells exhibited a higher expression of miR-210-3p compared to MRC-5 (Figure 1B). Also, A549 cells showed a maximal fold-change in miR-210-3p expression. Next, to study the correlation between miR-210-3p expression and lung cancer patient survival, the overall survival probabilities of 50

lung cancer patients were estimated using the Kaplan–Meier method with respect to miR-210-3p expression. The survival data showed that patients with high expression of miR-210-3p had a poor overall survival compared to those with low expression (Figure 1C).

Subsequently, the clinical data of 50 patients with NSCLC enrolled in this study were analyzed, and the correlation between the clinical parameters of these patients and the expression of miR-210-3p was analyzed. We found that the expression of miR-210-3p was not directly related to the patient's age, gender, pathological types, smoking and metastasis. Compared to patients at stage I–II, the expression of hsa-miR-210-3p was enhanced markedly in patients at stage III. The expression of miR-210-3p in the tissues of patients with moderate and high differentiation was significantly higher than that in the tissues of patients with low differentiation (Table 3). Taken together, these data supported the conclusion that miR-210-3p is expressed at a high level in NSCLC.

### Inhibition of miR-210-3p Inhibited A549 Cell Viability, Migration, and Invasion While Inducing Apoptosis

Next, we characterized the functional role of miR-210-3p in lung cancer. A549 cells were treated with miR-210-3p-specific inhibitor (Figure 2A) and assayed for the viability, apoptosis, migration, and invasion in vitro by CCK-8 test, flow cytometry, and transwell chamber assays. The results displayed inhibition of miR-210-3p by specific inhibitor, which hindered lung cancer cell viability, migration, and invasion but facilitated apoptosis (Figure 2B–D). Subsequently, the expression of pro-apoptotic protein Bax, anti-apoptotic protein Bcl-2, and metastatic markers MMP-2 and MMP-9 were determined by immunoblotting. The data showed that the inhibition of miR-210-3p diminished the expression of Bcl-2, MMP-2, and MMP-9 but increased the expression of Bax (Figure 2E). Bcl-2 and Bax are the most important inhibitors of apoptosis and pro-apoptotic genes. The expression of MMP2 and MMP9 was related to tumor invasion and metastasis. Therefore, this phenomenon illustrated the carcinogenic function of miR-210-3p.

### miR-210-3p Targeted the Transcription Factor USFI in A549 Cells


In the following experiments, we recapitulated the molecular mechanisms underlying miR-210-3p in lung cancer.

hTFtarget is a comprehensive database to identify the regulatory factors of human transcription and their targets related to lung tissues. Additionally, we searched for predicted miR-210-3p targets in the TargetScan database. Subsequently, five common transcription factors were identified as putative miR-210-3p targets: ASCL1, SIN3A, USF1, STAT1, and YY1 (Figure 3A). Real-time qPCR displayed that *ASCL1*, *SIN3A*, *USF1*, *STAT1*, and *YY1* were poorly expressed in tumor lung tissues compared to matched tumor-free lung tissues (Figure 3B). We also observed that USF1 showed a maximal fold-change between tumor lung tissues and tumor-free lung tissues. The Cancer Genome Atlas (TCGA) and GTEx databases show that USF1 was poorly expressed in lung adenocarcinoma and lung squamous cell carcinoma compared to normal tissues (Figure 3C). The expression of miR-210-3p was negatively correlated with the expression of USF1 in lung cancer tissues (Figure 3D). Immunoblotting analysis also demonstrated the downregulation of USF1 in tumor lung tissues compared to matched tumor-free lung tissues and in lung cancer cell lines (A549, A-427, NCI-H209, and NCI-H23) compared to MRC-5 (Figure 3E and F). The regulation of miR-210-3p on USF1 was further demonstrated by luciferase assays; decreased luciferase activity was observed at the promoter of the reporter gene containing USF1-Wt compared to that containing USF1-Mut in the presence of miR-210-3p mimic (Figure 3G). Furthermore, USF1 was enriched at the AGO2 promoter region, as assessed by immunoprecipitation using anti-AGO2 antibody relative to normal IgG (Figure 3H), suggesting that USF1 could bind to miR-210-3p.

Similarly, immunoblotting showed an elevated expression of USF1 in response to miR-210-3p inhibition in A549 cells (Figure 3I).

### miR-210-3p Diminished PCGF3 by Targeting USF1 in A549 Cells

Herein, we attempted to identify genes downstream of USF1. The hTFtarget database showed that USF1 regulates *PCGF3* gene. TCGA and GTEx databases showed that *PCGF3* was poorly expressed like USF1 in lung adenocarcinoma and lung squamous cell carcinoma compared to normal tissues (Figure 4A). Therefore, we proposed a hypothesis that miR-210-3p diminishes the activity of *PCGF3* by targeting USF1. Real-time qPCR and immunoblotting analysis demonstrated that *PCGF3* was poorly expressed in tumor lung tissues compared to matched tumor-free lung tissues (Figure 4B and C). The expression of *PCGF3* was positively correlated with USF1 in lung cancer tissues (Figure 4D). Immunoblotting analysis also demonstrated downregulated *PCGF3* in lung cancer cell lines (A549, A-427, NCI-H209, and NCI-H23) compared to that in MRC-5 cells (Figure 4E). The JASPAR database showed the presence of USF1 binding sites at the *PCGF3* promoter region (Figure 4F), which was confirmed by luciferase assays, as evidenced by enhanced luciferase activity at the promoter of the reporter gene containing *PCGF3*-Wt compared to that containing *PCGF3*-Mut under USF1 overexpression (Figure 4G). Then, A549 cells were subjected to ChIP assay using anti-USF1 or normal mouse IgG. We found that anti-USF1 immunoprecipitated *PCGF3* relative to IgG (Figure 4H),



**Figure 1** Upregulated miR-210-3p is associated with poor prognosis of lung cancer. The expression of miR-210-3p was analyzed by real-time qPCR in 50 tumor lung tissues compared to matched adjacent tumor tissues (A) and in lung cancer cell lines (A549, A-427, NCI-H209, and NCI-H23) compared to normal lung epithelial cell line BEAS-2B (B). (C) Overall survival probabilities of 50 lung cancer patients were estimated according to miR-210-3p expression using the Kaplan-Meier method and analyzed by Log rank test. \* $p < 0.05$  compared to matched adjacent tumor tissues by paired t-test and to MRC-5 by ANOVA adjusted by Tukey's test.

**Table 3** Correlation Between miR-210-3p Expression and Clinicopathological Parameters of Patients with NSCLC (n, %)

Clinical Features	miR-210-3p		p-value
	Low Expression	High Expression	
Gender			0.421
Male	16 (57.14%)	12 (42.86%)	
Female	10 (45.45%)	12 (54.55%)	
Age (median age = 58 years)			0.545
<58	9 (37.50%)	15 (62.50%)	
≥58	10 (38.46%)	16 (61.54%)	
Smoking			0.061
Non-smoker	6 (46.15%)	7 (53.85%)	
Smoker	12 (32.43%)	25 (67.57%)	
Clinical stage			0.038
I–II	6 (28.57%)	15 (71.43%)	
III	12 (41.38%)	17 (58.62%)	
Metastasis (pN)			0.154
N0–N1	13 (44.83%)	16 (55.17%)	
N2	8 (38.10%)	13 (61.90%)	
Pathological types			0.204
Squamous cell carcinoma	7 (31.82%)	15 (68.18%)	
Adenocarcinoma	8 (32.00%)	17 (68.00%)	
Others	1 (33.33%)	2 (66.67%)	
Organizational rating			0.027
Moderate and high differentiation	14 (41.18%)	20 (58.82%)	
Low differentiation	4 (25.00%)	12 (75.00%)	

suggesting that the transcription factor USF1 binds to PCGF3 and promotes its transcription. To further ascertain the functional regulation of USF1 on PCGF3, two species of sh-USF1 were designed and transfected into A549 cells to establish USF1 knockdown A549 cells. Immunoblotting analysis demonstrated diminished USF1 in A549 cells treated by two pieces of sh-USF1, respectively. We selected the sh-USF1-2 that silenced USF1 profoundly (Figure 4I). Subsequently, we established USF1-overexpressed A549 cells using the expression vector containing the *USF1* gene and USF1 knockdown A549 cells using sh-USF1. Immunoblotting analysis demonstrated an elevated expression of PCGF3 in USF1-overexpressed A549 cells and decreased expression of PCGF3 in USF1 knockdown A549 cells (Figure 4J). Moreover, A549 cells


were treated with miR-210-3p inhibitor and sh-USF1 shRNA. Real-time qPCR and immunoblotting analysis (Figure 4K and L) demonstrated that miR-210-3p inhibitor increases the expression of USF1 and PCGF3 in A549 cells. USF1 knockdown did not affect the expression of miR-210-3p but diminished the expression of PCGF3 in A549 cells treated with miR-210-3p inhibitor. These data proved our hypothesis that miR-210-3p diminishes the activity of PCGF3 by targeting USF1 in A549 cells.

### miR-210-3p Facilitated A549 Cell Viability, Migration, and Invasion While Inducing Apoptosis by Inhibiting PCGF3

Owing to the regulation of miR-210-3p on USF1 and PCGF3, we aimed to dissect whether the miR-210-3p/USF1/PCGF3 axis is implicated in the development of lung cancer. Two pieces of sh-PCGF3 were designed and independently transfected to achieve PCGF3 knockdown in A549 cells. Immunoblotting analysis demonstrated diminished PCGF3 in A549 cells treated by two sh-PCGF3, respectively (Figure 5A). The sh-PCGF3 that silenced PCGF3 profoundly was selected for the following studies. Next, A549 cells were treated by miR-210-3p inhibitor and sh-PCGF3, wherein miR-210-3p inhibition-mediated downregulation of USF1 and PCGF3, and PCGF3 knockdown was verified by real-time qPCR and immunoblotting analysis (Figure 5B and C). Subsequently, A549 cells treated with both miR-210-3p inhibitor and sh-PCGF3 were assayed to evaluate their viability, apoptosis, migration, and invasion in vitro. miR-210-3p inhibition interfered with lung cancer cell viability, migration, and invasion and facilitated apoptosis, which was reversed by PCGF3 knockdown (Figure 5D–F). We also observed elevated expression of MMP-2, MMP-9, and Bcl-2 and decreased the expression of Bax in A549 cells treated with miR-210-3p inhibitor and sh-PCGF3 compared to A549 cells treated with miR-210-3p inhibitor alone (Figure 5G). The above results suggested that miR-210-3p facilitates lung cancer cell viability, migration, and invasion while inducing apoptosis by inhibiting PCGF3.

### miR-210-3p Delayed the Development and Metastasis of Lung Cancer in vivo by Inhibiting PCGF3

Finally, we injected miR-210-3p antagomir alone or with sh-PCGF3 into mice xenografted with A549 cells after implantation duration of 8 days. Real-time qPCR and




**Figure 2** Inhibition of miR-210-3p diminishes A549 cell viability, migration, and invasion while inducing apoptosis. **(A)** Verification of miR-210-3p inhibition in A549 cells treated with miR-210-3p inhibitor by real-time qPCR. **(B)** Viability of A549 cells treated with miR-210-3p inhibitor was examined by CCK-8 assays. **(C)** Apoptosis of A549 cells treated with miR-210-3p inhibitor was analyzed by flow cytometry. **(D)** Representative view ( $\times 200$ ) of A549 cells treated with miR-210-3p inhibitor migrating from upper transwell chambers into lower well and statistics of migrating cells; Representative view ( $\times 200$ ) of cells invading from Matrigel-coated chambers into lower wells and statistics of invading cells. **(E)** Immunoblots and quantification of Bax, Bcl-2, MMP-2, and MMP-9 in A549 cells treated with miR-210-3p inhibitor. \* $p < 0.05$  compared to NC inhibitor by unpaired *t*-test or by repeated measurement ANOVA adjusted by Bonferroni test (only for **B**).

immunoblotting analyzed the miR-210-3p inhibition-mediated downregulation of USF1 and PCGF3 and PCGF3 knockdown in mice (Figure 6A and B). The growth of lung cancer xenografts in mice was monitored every 3 days after implantation duration of 8 days (Figure 6C). The data showed that intravenous injection of miR-210-3p antagomir alone delayed the growth of lung cancer xenografts in mice, while intravenous injection of miR-210-3p antagomir and sh-PCGF3 in combination negated the effect of miR-210-3p antagomir on the growth of lung cancer xenografts in mice. Lymph nodes surrounding tumor xenografts were resected for HE staining. Histopathological changes (Figure 6D) were detected by purplish-red and spindle-shaped cells and fewer lymph nodes in xenograft mice with intravenous injection of miR-210-3p antagomir alone. Compared to these xenograft mice, faded cells and a large number of lymph nodes were observed in xenografted mice with intravenous injection of a combination of miR-210-3p antagomir and sh-PCGF3. Moreover, we performed immunoblotting analysis to determine the expression of Bax, Bcl-2, MMP-2, and MMP-9 in tissues of lung cancer xenografts. The

intravenous injection of miR-210-3p antagomir diminished the expression of Bcl-2, MMP-2, and MMP-9 but increased the expression of Bax, which was reversed by intravenous injection of sh-PCGF3 (Figure 6E). These data suggested that miR-210-3p delays the development and metastasis of lung cancer *in vivo* by inhibiting PCGF3.

## Discussion


Lung cancer is the most frequently occurring aggressive tumor with increasing morbidity worldwide.<sup>16</sup> The 5-year survival rate of lung cancer is poor due to the high invasion and metastasis of tumors.<sup>3</sup> In recent years, multiple miRNAs have been reported to play a functional role in the occurrence and progression of lung cancer.<sup>5</sup> The present study explored the effects of miR-210-3p on cell viability, migration, invasion, and apoptosis in lung cancer. Taken together, the current findings provided evidence that the downregulation of miR-210-3p elevated PCGF3 by upregulating USF1 expression, thereby suppressing the viability, migration, and invasion while inducing apoptosis, which alleviated the progression of lung cancer.




**Figure 3** Transcription factor *USF1* is the target gene of miR-210-3p in A549 cells. (A) Venn plot showing 5 common transcription factors as putative miR-210-3p targets, ASCL1, SIN3A, USF1, STAT1, and YY1 between the hTFtarget database ([http://bioinfo.life.hust.edu.cn/hTFtarget#/?](http://bioinfo.life.hust.edu.cn/hTFtarget#/)) and TargetScan database ([http://www.targetscan.org/vert\\_71/](http://www.targetscan.org/vert_71/)). (B) Real-time qPCR examined the expression of *ASCL1*, *SIN3A*, *USF1*, *STAT1*, and *YY1* in 50 tumor lung tissues compared to matched tumor-free lung tissues. (C) *USF1* was poorly expressed in lung adenocarcinoma and lung squamous cell carcinoma compared to normal tissues in TCGA and GTEx databases (<http://gepia2.cancer-pku.cn/#index>). (D) Pearson's correlation analysis demonstrated a negative correlation between the expression of miR-210-3p and *USF1* in lung cancer tissues. (E and F) Immunoblots and quantification of *USF1* in tumor lung tissues ( $n = 50$ ), matched tumor-free lung tissues ( $n = 50$ ), lung cancer cell lines (A549, A-427, NCI-H209, and NCI-H23), and MRC-5. (G) Luciferase activity at the promoter of the reporter gene containing *USF1*-WT and *USF1*-Mut in response to miR-210-3p-mimic treatment in HEK-293T cells. (H) *USF1* was enriched at the AGO2 promoter region in the immunoprecipitation using anti-AGO2 antibody relative to normal IgG. (I) Immunoblots and quantification of *USF1* in A549 cells treated with miR-210-3p inhibitor. \* $p < 0.05$  compared to matched tumor-free lung tissues by paired *t*-test, to MRC-5 by ANOVA adjusted by Tukey's test, to NC mimic, normal IgG, and NC inhibitor by unpaired *t*-test.

Initially, our results implied that miR-210-3p was upregulated in lung cancer tissues and cells, which was associated with a poor prognosis of the cancer. Thus, it could be speculated that inhibition of miR-210-3p inhibited A549 cell viability, migration, and invasion while inducing apoptosis in lung cancer. Accumulating evidence has


recently indicated that aberrant expression of miRNAs is implicated in multiple human cancers, including lung cancer.<sup>2</sup> For instance, miR-29c regulates cell proliferation and cellular apoptosis that in turn affects the tumor progression of NSCLC.<sup>3</sup> Existing literature reported that miR-18a-5p is upregulated in NSCLC, and it promotes cell



**Figure 4** miR-210-3p diminishes the activity of PCGF3 by targeting USF1 in A549 cells. **(A)** PCGF3 was poorly expressed in lung adenocarcinoma and lung squamous cell carcinoma compared to normal tissues in TCGA and GTEx databases. **(B)** Real-time qPCR examined the expression of PCGF3 in tumor lung tissues ( $n = 50$ ) and matched tumor-free lung tissues ( $n = 50$ ). **(C)** Immunoblots and quantification of PCGF3 in tumor lung tissues ( $n = 50$ ) and matched tumor-free lung tissues ( $n = 50$ ). **(D)** Pearson's correlation analysis demonstrated a positive correlation between the expression of PCGF3 and USF1 in lung cancer tissues. **(E)** Immunoblots and quantification of PCGF3 in lung cancer cell lines (A549, A-427, NCI-H209, and NCI-H23) and MRC-5. **(F)** Putative USF1 binding sites in the PCGF3 promoter region by the JASPAR database analysis. **(G)** The luciferase activity at the promoter of the reporter gene containing PCGF3-Wt and PCGF3-Mut in response to USF1 overexpression treatment in HEK-293T cells. **(H)** Anti-USF1 immunoprecipitated more PCGF3 relative to IgG by ChIP assays. **(I)** Two sh-USF1s were designed and independently delivered into A549 cells to construct USF1 knockdown A549 cells. **(J)** Immunoblots and quantification of USF1 and PCGF3 in A549 cells with USF1 overexpression or knockdown. **(K)** Real-time qPCR examined the expression of miR-210-3p in A549 cells treated with miR-210-3p inhibitor alone or with sh-USF1. **(L)** Immunoblots and quantification of USF1 and PCGF3 in A549 cells treated with miR-210-3p inhibitor alone or sh-USF1. \* $p < 0.05$  compared to matched adjacent tumor tissues by paired  $t$ -test, to sh-NC or IgG by unpaired  $t$ -test, to MRC-5 or NC inhibitor + sh-NC by ANOVA adjusted by Tukey's test. # $p < 0.05$  compared to oe-NC by unpaired  $t$ -test and to miR-210-3p inhibitor + sh-NC by ANOVA adjusted by Tukey's test.



**Figure 5** miR-210-3p facilitates A549 cell viability, migration, and invasion but induces apoptosis by inhibiting PCGF3. **(A)** Two pieces of sh-PCGF3 were designed and independently delivered into A549 cells to construct USF1 knockdown A549 cells. **(B)** Real-time qPCR examined the expression of miR-210-3p in A549 cells treated with miR-210-3p inhibitor alone or with sh-PCGF3. **(C)** Immunoblots and quantification of USF1 and PCGF3 in A549 cells treated with miR-210-3p inhibitor alone or with sh-PCGF3. **(D)** Viability of A549 cells treated with miR-210-3p inhibitor alone or with sh-PCGF3 was examined by CCK-8 assays. **(E)** Apoptosis of A549 cells treated with miR-210-3p inhibitor alone or with sh-PCGF3 was analyzed by flow cytometry. **(F)** Representative view ( $\times 200$ ) of A549 cells treated with miR-210-3p inhibitor alone or with sh-PCGF3 migrating from upper into lower chambers and statistics of migrating cells; Representative view ( $\times 200$ ) of cells invading from Matrigel-coated chambers into lower wells and statistics of invading cells. **(G)** Immunoblots and quantification of Bax, Bcl-2, MMP-2, and MMP-9 in A549 cells treated with miR-210-3p inhibitor alone or with sh-PCGF3. \* $p < 0.05$  compared to sh-NC or NC inhibitor + sh-NC and # $p < 0.05$  compared to miR-210-3p inhibitor + sh-NC by ANOVA adjusted by Tukey's test or by repeated measurements ANOVA adjusted by Bonferroni test (only for **D**).




**Figure 6** miR-210-3p delays the development and metastasis of lung cancer in vivo by inhibiting PCGF3. **(A)** Real-time qPCR examined the expression of miR-210-3p in tissues of lung cancer xenografts in mice with intravenous injection of miR-210-3p antagonist alone or with sh-PCGF3. **(B)** Immunoblots and quantification of USF1 and PCGF3 in tissues of lung cancer xenografts in mice with intravenous injection of miR-210-3p antagonist alone or with sh-PCGF3. **(C)** Growth of lung cancer xenografts in mice with intravenous injection of miR-210-3p antagonist alone or with sh-PCGF3 was monitored every 3 days after implantation duration of 8 days. **(D)** Histopathological changes (×200) of lung tissues and lymph node metastasis in xenograft mice with intravenous injection of miR-210-3p antagonist alone or with sh-PCGF3. **(E)** Immunoblots and quantification of Bax, Bcl-2, MMP-2, and MMP-9 in tissues of lung cancer xenografts in mice with intravenous injection of miR-210-3p antagonist alone or with sh-PCGF3. \**p* < 0.05 compared to NC antagonist + sh-NC and #*p* < 0.05 compared to miR-210-3p antagonist + sh-NC by ANOVA adjusted by Tukey's test or by repeated measurements ANOVA adjusted by Bonferroni test (only for C). Sample size of six mice in each study group.

proliferation and migration, tumor growth, and metastasis of NSCLC both in vitro and in vivo to aggravate lung cancer.<sup>17</sup> miR-210 is also shown to play a significant role in a variety of tumor biological functions, including tumor proliferation, survival, and metastasis via regulation of target genes.<sup>10</sup> Notably, miR-210-3p is highly expressed in different cancers, including lung cancer, which is related to the poor survival rate of lung cancer patients, and it

affects the progression of the disease by regulating apoptosis, angiogenesis, and tumor growth.<sup>18</sup> miR-210-3p also promotes the invasion and EMT of lung cancer cells to enhance the progression of the cancer.<sup>11</sup> Therefore, silencing of miR-210-3p could be considered as a potential therapeutic target to reverse lung cancer.

Moreover, bioinformatics analysis and dual-luciferase reporter gene assay together validated that miR-210-3p targets



**Figure 7** Graphical summary of the mechanism of miR-210-3p in regulating lung cancer progression. miR-210-3p facilitates lung cancer development and metastasis by impairing USF1-mediated promotion of PCGF3.

USF1 and suppresses USF1 expression in lung cancer cells. It is known that miRNAs function as the oncogene or tumor suppressor in the etiology and pathogenesis of cancer by targeting tumor suppressors or oncogenes.<sup>6</sup> A recent study demonstrated that USF1 acts as a modulator in protein expression and tumor biology.<sup>12</sup> Furthermore, it has been implicated that USF1, a ubiquitously expressed transcription factor, increases the expression of brain tumors.<sup>19</sup> Accumulating evidence has also shown that the upregulation of USF1 inhibits lung metastasis that delays the progression of lung cancer,<sup>13</sup> suggesting that the overexpression of USF1 serves as a biomarker for lung cancer. Taken together, these findings supported that restoration of USF1 underlies the anti-oncogenic effect of miR-210-3p by stimulating cell viability, migration, and invasion while repressing the apoptosis in lung cancer.

Additionally, the present study confirmed that miR-210-3p diminishes PCGF3 by targeting USF1 in A549 cells. A recent study confirmed that PCGF3 requires an interaction with the USF1 DNA binding transcription factor.<sup>14</sup> It contains a C3HC4-type RING finger, which is involved in lung cancer via cell cycle and tumor growth regulation<sup>15</sup>; however, the underlying mechanisms of PCGF3 in lung cancer remain to be investigated further. Thus, combining previous studies with our results, a regulatory network could be proposed in the anti-tumor progression, ie, the depletion of miR-210-3p inhibited A549 cell viability, migration, and invasion while stimulating the apoptosis by promoting USF1 expression to upregulate PCGF3.

## Conclusion

In conclusion, the current study demonstrated that miR-210-3p inhibits the expression of USF1, which potentially suppresses cell viability, migration, and invasion and triggers apoptosis to aggravate lung cancer through inhibition of

PCGF3 expression (Figure 7). This study also provided further insight into the regulatory network and the underlying roles of miR-210-3p-mediated regulation of PCGF3 via USF1 in lung cancer. Nonetheless, A549 is a lung adenocarcinoma cell line, which only represents the type of lung adenocarcinoma in lung cancer, and other types need more matching cell lines for generalization of data. Additional studies are required to adequately define the detailed mechanisms underlying miR-210-3p interaction with USF1 and PCGF3 and the influence on lung cancer progression.

## Abbreviations

miRNAs, microRNAs; NSCLCs, non-small cell lung cancers; 3'-UTR, 3'-untranslated region; USF1, upstream stimulating factor 1; FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; PI, propidium iodide; HE, hematoxylin–eosin; ANOVA, analysis of variance; TCGA, The Cancer Genome Atlas.

## Data Sharing Statement

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

## Ethics Approval and Informed Consent

Subjects were included using informed consent for a protocol approved by the Ethics committee of People's Hospital of Ningxia Hui Autonomous Region [2019] No. 027. Animal studies were performed with the approval from the Institutional Animal Care and Use Committee of People's Hospital of Ningxia Hui Autonomous Region [2019] No. 027.

## Funding

This work was supported by the Ningxia Hui Autonomous Region Key R&D Program General Project (Fund Code:

2019BEG03045); Basic research projects of central universities (fund number: 1920160100).

## Disclosure

The authors declare that they have no competing interests.

## References

- Du X, Zhang J, Wang J, Lin X, Ding F. Role of miRNA in lung cancer-potential biomarkers and therapies. *Curr Pharm Des*. 2018;23(39):5997–6010. doi:10.2174/1381612823666170714150118
- Zhang Y, Wang Y, Wang J. MicroRNA-584 inhibits cell proliferation and invasion in non-small cell lung cancer by directly targeting MTDH. *Exp Ther Med*. 2018;15(2):2203–2211. doi:10.3892/etm.2017.5624
- Zhan S, Wang C, Yin F. MicroRNA-29c inhibits proliferation and promotes apoptosis in non-small cell lung cancer cells by targeting VEGFA. *Mol Med Rep*. 2018;17(5):6705–6710. doi:10.3892/mmr.2018.8678
- Sun F, Li L, Yan P, et al. Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance. *Nat Commun*. 2019;10(1):5324. doi:10.1038/s41467-019-13331-x
- Lu C, Xie Z, Peng Q. MiRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer. *Am J Cancer Res*. 2017;7(9):1863–1873.
- Zhang G, Zheng H, Zhang G, et al. MicroRNA-338-3p suppresses cell proliferation and induces apoptosis of non-small-cell lung cancer by targeting sphingosine kinase 2. *Cancer Cell Int*. 2017;17:46. doi:10.1186/s12935-017-0415-9
- Li G, Fang J, Wang Y, Wang H, Sun CC. MiRNA-based therapeutic strategy in lung cancer. *Curr Pharm Des*. 2018;23(39):6011–6018. doi:10.2174/1381612823666170725141954
- Chen Y, Min L, Ren C, et al. miRNA-148a serves as a prognostic factor and suppresses migration and invasion through Wnt1 in non-small cell lung cancer. *PLoS One*. 2017;12(2):e0171751. doi:10.1371/journal.pone.0171751
- Chen S, Shi F, Zhang W, Zhou Y, Huang J. miR-744-5p inhibits non-small cell lung cancer proliferation and invasion by directly targeting PAX2. *Technol Cancer Res Treat*. 2019;18:1533033819876913. doi:10.1177/1533033819876913
- Yang X, Shi L, Yi C, Yang Y, Chang L, Song D. MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1. *Am J Cancer Res*. 2017;7(8):1738–1753.
- Zhang X, Sai B, Wang F, et al. Hypoxic BMSC-derived exosomal miRNAs promote metastasis of lung cancer cells via STAT3-induced EMT. *Mol Cancer*. 2019;18(1):40. doi:10.1186/s12943-019-0959-5
- Ikedo R, Nishizawa Y, Tajitsu Y, et al. Regulation of major vault protein expression by upstream stimulating factor 1 in SW620 human colon cancer cells. *Oncol Rep*. 2014;31(1):197–201. doi:10.3892/or.2013.2818
- Kim KC, Yun J, Son DJ, et al. Suppression of metastasis through inhibition of chitinase 3-like 1 expression by miR-125a-3p-mediated up-regulation of USF1. *Theranostics*. 2018;8(16):4409–4428. doi:10.7150/thno.26467
- Scelfo A, Fernández-Pérez D, Tamburri S, et al. Functional landscape of PCGF proteins reveals both RING1A/B-Dependent-and RING1A/B-independent-specific activities. *Mol Cell*. 2019;74(5):1037–1052. e1037. doi:10.1016/j.molcel.2019.04.002
- Kitamura S, Tanahashi T, Aoyagi E, et al. Response predictors of S-1, cisplatin, and docetaxel combination chemotherapy for metastatic gastric cancer: microarray analysis of whole human genes. *Oncology*. 2017;93(2):127–135. doi:10.1159/000464329
- Wu Y, Zhang J, Hong Y, Wang X. Effects of kanglaite injection on serum miRNA-21 in patients with advanced lung cancer. *Med Sci Monit*. 2018;24:2901–2906. doi:10.12659/MSM.909719
- Liang C, Zhang X, Wang HM, et al. MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer. *Cell Death Dis*. 2017;8(5):e2764. doi:10.1038/cddis.2017.145
- Świtlik W, Karbownik MS, Suwalski M, Kozak J, Szemraj J. miR-30a-5p together with miR-210-3p as a promising biomarker for non-small cell lung cancer: a preliminary study. *Cancer Biomarkers*. 2018;21(2):479–488. doi:10.3233/CBM-170767
- Zhang L, Handel MV, Schartner JM, et al. Regulation of IL-10 expression by upstream stimulating factor (USF-1) in glioma-associated microglia. *J Neuroimmunol*. 2007;184(1–2):188–197. doi:10.1016/j.jneuroim.2006.12.006

### OncoTargets and Therapy

Dovepress

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>